// App-Quantinova.ai

789 : Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)

Researchers

Presenter

  • Amod Sarnaik

Principal Investigators

  • Harriet Kluger

  • Omid Hamid

  • Eric Whitman

  • Sajeve Thomas

  • Martin Wermke

  • Mike Cusnir

  • Evidio Domingo-Musibay

  • Giao Phan

  • John Kirkwood

  • Jessica Hassel

  • Marlana Orloff

  • James Larkin

  • Jeffrey Weber

  • Andrew Furness

  • Nikhil Khushalani

  • Theresa Medina

  • Friedrich Finckenstein

  • Madan Jagasia

  • Parameswaran Hari

  • Giri Sulur

  • Wen Shi

  • Xiao Wu

  • Jason Chesney

Medical Centers

  • UPMC Hillman Cancer Center, Pittsburgh, PA, USA

  • Lee Moffitt Cancer Center, Tampa, FL, USA

  • Atlantic Health System Cancer Care, Morristown, NJ

  • Skin Cancer Center, University Hospital Heidelberg, Heidelberg, Germany

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

  • The Angeles Clinic & Research Institute, A Cedar-Sinai Affiliate, Los Angeles, CA

  • Royal Free Hospital NHS FoundationTrust, London, UK

  • Orlando Health Heart Institute, Orlando, FL

  • Thomas Jefferson University Kimmel Cancer Center, Philadelphia, PA

  • Mount Sinai Medical Center, Miami Beach, FL

  • University of Minnesota Masonic Cancer Research Center, Minneapolis, MN

  • UofL Health – Brown Cancer Center, University of Louisville, Louisville, KY, USA

  • University of Colorado Cancer Center Anschutz Medical Campus, Denver, CO

  • Technical University Dresden, NCT/UCC Early Clinical Trial Unit, Dresden, Germany

  • Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA

  • Yale School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • Glomeruloid microvascular proliferation

  • Interleukin-2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02360579

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved